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ASPP1 and ASPP2 are activators of p53-dependent
apoptosis, whereas iASPP is an inhibitor of p53.
Binding assays showed differential binding for C-
terminal domains of iASPP and ASPP2 to the core
domains of p53 family members p53, p63, and p73.
We also determined a high-resolution crystal struc-
ture for the C terminus of iASPP, comprised of four
ankyrin repeats and an SH3 domain. The crystal lat-
tice revealed an interaction between eight sequential
residues in one iASPP molecule and the p53-binding
site of a neighboring molecule. ITC confirmed that
a peptide corresponding to the crystallographic
interaction shows specific binding to iASPP. The
contributions of ankyrin repeat residues, in addition
to those of the SH3 domain, generate distinctive ar-
chitecture at the p53-binding site suitable for inhibi-
tion by small molecules. These results suggest that
the binding properties of iASPP render it a target
for antitumor therapeutics and provide a peptide-
based template for compound design.
INTRODUCTION
The discovery of the apoptosis stimulating protein of p53 (ASPP)
family of proteins revealed a new level of p53 regulation. There
are three family members in humans ASPP1, ASPP2, and iASPP.
ASPP1 and ASPP2 selectively stimulate the transactivation func-
tion of all three p53 family members p53, p63, and p73, increas-
ing the transactivation of proapoptotic genes (Bergamaschi
et al., 2004; Samuels-Lev et al., 2001). In contrast, iASPP is an
oncoprotein that specifically inhibits p53; its overexpression
confers resistance to apoptosis induced by UV radiation and ex-
posure to the chemotherapeutic agent cisplatin in cultured cells
(Bergamaschi et al., 2003). There is only one ASPP family mem-
ber in C. elegans, which is functionally interchangeable with hu-
man iASPP (Bergamaschi et al., 2003), thus iASPP is likely to be
the most ancient member of the ASPP family. Full-length human
iASPP consists of 828 amino acids and is the isoform almost ex-
clusively expressed in cells (Slee et al., 2004). iASPP only shares
high sequence homology with ASPP1 and ASPP2 in the C-termi-
nal region (230 amino acids), which is made up of four ankyrinStructure 16,repeats and an SH3 domain, two common structural motifs in-
volved in protein-protein interactions. In all members of the
ASPP family, this C-terminal region binds to theDNA-binding do-
main of p53 and, in iASPP, is required for the inhibitory effect
(Bergamaschi et al., 2003; Slee et al., 2004). The crystal structure
of the C-terminal region of ASPP2 in complexwith theDNA-bind-
ing domain of p53 revealed that the ankyrin repeats and SH3
domain of ASPP2 both contribute to the p53-binding-site unit
(Gorina and Pavletich, 1996).
The tumor suppressor protein p53, the prototypic member of
the p53 family, is a transcription factor that responds to onco-
genic stress such as DNA damage by activating genes that result
in apoptosis and cell-cycle arrest (for review, see Vogelstein
et al. [2000]). p53 is a primary target for mutation in human
cancer; it is estimated that mutations or loss of function of p53
accounts for half of all cancers. The mutation frequency of p53
varies among different tumor types so that it can be much lower
than 50%, for example 30% in breast cancer and only 5% in
leukemia (Soussi et al., 2005). Most p53 mutations map to the
DNA-binding domain, they are therefore unable to activate
genes upregulated by wild-type p53, a loss of function that ulti-
mately results in unchecked cell division (Cho et al., 1994). Full-
length p63 and p73, like p53, have the ability to transactivate p21
and Bax genes causing cell-cycle arrest and apoptosis (Di Como
et al., 1999; Gaiddon et al., 2001). Unlike p53, p63 and p73 have
different isoforms (for review, see Yang et al. [2002]); isoforms
lacking the transactivation domain act as dominant negative in-
hibitors of p53 (Kaghad et al., 1997; Laan and Paabo, 1998; Yang
et al., 1998). p63 and p73 knockout mice show defects in epider-
mal (Mills et al., 1999; Yang et al., 1999) and neuronal (Pozniak
et al., 2002; Yang et al., 2000) development, respectively, but
do not form spontaneous tumors as is the case for p53 knockout
mice (Donehower et al., 1992); the murine knockout phenotypes
aremirrored in human disease.Mutations in p63 and p73 are rare
in human cancer but a number of mutations in the DNA-binding
domain and sterile amotif of p63 are associatedwith genetic epi-
dermal syndromes (van Bokhoven and McKeon, 2002). Overex-
pression of p73 triggers neuronal cell differentiation in vitro (De
Laurenzi et al., 2000). There is also an important functional rela-
tionship between the p53 family members: in the absence of p63
and p73, p53-dependent apoptosis in response to DNA damage
is severely impaired (Flores et al., 2002).
The expression levels of ASPP proteins are altered in tumors.
While ASPP1 and ASPP2 are downregulated in a large percent-
age of tumors (Agirre et al., 2006; Bergamaschi et al., 2003; Liu259–268, February 2008 ª2008 Elsevier Ltd All rights reserved 259
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is upregulated in human breast carcinomas expressing wild-type
p53 (Bergamaschi et al., 2003). iASPP is also overexpressed in
acute leukemias regardless of p53 mutation status (Zhang
et al., 2005), suggesting that iASPPmay promote carcinogenesis
by other mechanisms additional to p53 inhibition. As iASPP is
functionally distinct from the other family members, and an inhib-
itor of p53-dependent apoptosis upregulated in cancer, a strat-
egy based on antagonizing the ability of iASPP to bind p53 could
be an important target for treating cancer. With the exception of
thewell-characterized ASPP2-p53 interaction (Gorina and Pavle-
tich, 1996; Tidow et al., 2006), there is a paucity of information at
the molecular level on the interactions of these protein families.
We therefore sought to analyze the interaction characteristics
and specificities of the ASPP family C-terminal regions with the
DNA-binding domains of the p53 family.
A solid-phase binding assay revealed that the C-terminal re-
gion of iASPP (residues 625–828, named iASPPD625), like its ho-
mologs, is able to interact with the DNA-binding domains of p63
and p73. However, there were significant differences in the equi-
librium binding constants for iASPPD625 and the homologous
region in ASPP2. To further characterize the p53 binding site of
iASPP, we determined a high-resolution (2.1 A˚) crystal structure
Figure 1. Saturation Curves and Scatchard
Plots for the Binding of iASPPD608 and
ASPP2D905 to p53core, p63core, and p73core
Each value represents the mean and standard
deviation of duplicate measurements, error bars
represent the standard deviation of duplicate
measurements.
of the iASPPC-terminal domain (residues
608–828, named iASPPD608). A fortu-
itous lattice packing in the iASPPD608
crystals revealed that the first eight or-
dered N-terminal residues of one mole-
cule can interact with the putative p53
binding site of a second molecule. Sub-
sequent studies using isothermal titration
calorimety (ITC) confirmed that an 8-mer
peptide, corresponding to iASPP resi-
dues 616–623, shows binding specificity
to the C-terminal region of iASPP.
RESULTS
Differential Binding of iASPP and
ASPP2 to the p53 Family
We investigated whether the C-terminal
domains of iASPP and ASPP2, iASPP
residues 625–828 (iASPPD625), and
ASPP2 residues 905–1128 (ASPP2D905)
bind the core DNA-binding domains of
p53, p63, and p73, p53 residues 94–
292 (p53core), p63 residues 123–323
(p63core), and p73 residues 112–312
(p73core) with varying affinities by using
a solid-phase binding assay. Assays
were performed as described in the Experimental Procedures
section. Nonlinear regression fitting of saturation curves re-
vealed that iASPPD625 and ASPP2D905 bind the DNA-binding
domains of all three p53 family members (Figure 1). Both
iASPPD625 and ASPP2D905 bind p53core with a similar high
affinity; equilibrium dissociation constants (Kd values) measured
were 26.4 ± 1.7 nM and 23.3 ± 1.6 nM, respectively. Values
measured for iASPPD625 and ASPP2D905 binding p63core
and p73core showed significant differences; iASPPD625 binds
p63core and p73core with an affinity approximately 3-fold higher
than that of ASPP2D905, and both iASPPD625 and ASPP2D905
have a 3-fold higher affinity for p63core over p73core. Kd values
for iASPPD625 and ASPP2D905 binding p63core were 128.1 ±
11 nM and 343.1 ± 39.8 nM, respectively, and for p73core,
331.3 ± 66 nM and 984.4 ± 196.1 nM, respectively.
Crystal Structure of the C-Terminal Region of iASPP
The crystal structure of the C-terminal domain of iASPP residues
608–828 (iASPPD608) was determined by molecular replace-
ment and refined to 2.1 A˚ resolution (see Experimental Proce-
dures section). There is one molecule in the asymmetric unit of
the crystal for which residues 616–822 are visible as ordered
electron density.
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ASPP proteins, the iASPP structure comprises four ankyrin re-
peats and a closely juxtaposed SH3 domain (Figure 2A), which
together constitutes one structural unit with a buried surface be-
tween the ankyrin repeats and SH3 domain of 1312 A˚2. Attempts
to express the SH3 domain alone in E. coli, either as a GST-
fusion or nontagged, were unsuccessful (data not shown),
suggesting that the ankyrin repeats and SH3 domain of the C-
terminal domain of iASPP are an indivisible structural unit. An-
kyrin repeats 1–3 are typical in their topology, each folds into
two antiparallel a helices followed by a b-hairpin loop, which
juts out at an angle of approximately 90 relative to the a helices.
The fourth repeat lacks the b-hairpin loop and has an extended
second helix. The interrepeat interface mainly consists of hydro-
phobic interactions, and a network of hydrogen bonds connects
the b-hairpin loops. There are two regions in the ankyrin repeats
that contain insertions compared to the ankyrin consensus:
a one residue insertion in the third ankyrin repeat located in the
Figure 2. Overall Structure of iASPPD608
(A) Cartoon presentation of the iASPPD608 struc-
ture. Cylinders represent helices and arrows
b strands. The ankyrin repeats are colored purple,
and the SH3 domain is cyan with the RT loop in
orange and n-Src loop in red. The N-terminal 12
residues are colored in blue.
(B) Sequence alignment of the C-terminal regions
of human and C. elegans ASPP proteins. The sec-
ondary structure elements of iASPPD608 are indi-
cated above the alignment and are colored as in
(A). The gray symbols above the sequences repre-
sent iASPP residues observed to interact with the
N-terminal residues (616–623) of a neighboring
molecule in the crystal lattice. The black symbols
below the sequences represent ASPP2 residues
involved in binding to the p53 DNA-binding do-
main in the ASPP2-p53 crystal structure (PDB
code: 1YCS). Arrow heads depict hydrogen
bonds, squares depict hydrophobic interactions,
and full arrows depict residues involved in both
hydrogen bonds and hydrophobic interactions.
The alignment was formatted with ESPript
(http://espript.ibcp.fr/ESPript/ESPript/).
hairpin loop (residues 715–726) and a
second insertion of two residues between
the two helices of the fourth ankyrin re-
peat (residues 734–742) forming an ex-
tended loop; these features are common
to ASPP proteins (Figure 2B). When com-
pared to those in ASPP2, the iASPP
ankyrin repeats (residues 627–754) have
a root mean square deviation (rmsd) of
1.2 A˚ for 127 equivalent Ca atoms.
The ankyrin repeats are connected to
the SH3 domain via the extended second
helix (residues 741–754) of the fourth an-
kyrin repeat, which is considerably longer
than the other helices of the previous re-
peats. Superpositions of the iASPP and
ASPP2 structures considering only the
SH3 domains or the ankyrin repeats, reveals a difference in the
relative orientation of their twomotifs of some 7 degrees, indicat-
ing that there is flexibility between these two domains
(Figure 3A). ASPP2 appears to be in a more open conformation,
this is mirrored by a lower buried surface area between the an-
kyrin repeats and the SH3 domain (1053 A˚2). A second iASPP
structure was determined (at 2.5 A˚ resolution, data not shown)
for a unit cell differing from that of the high-resolution structure
by up to 1 A˚; a comparison of the refined structures revealed
a difference in relative orientation of the ankyrin repeat and
SH3 domain of approximately 1 suggesting that there is flexibil-
ity between these domains.
The SH3 domain (residues 758–828) of iASPP displays the clas-
sical b-barrel-like fold typical of SH3 domains. It comprises five
antiparallel b strands (residues 762–765, 784–789, 798–803,
806–811, 815–816) and a 310 helical segment (residues 812–
814). SH3 domain sequences have a number of highly conserved
residues; the topology of an SH3 domain brings these conserved
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surface that forms a ligand-binding site. Two loops that make
a major contribution to this binding site have been termed the
RT-loop and the n-Src loop, classical SH3 domain nomenclature
(Figure 2). In iASPP, the RT-loop is of standard length, and the
n-Src loop contains a three-residue insertion (residues 793–795)
of mainly acidic residues. The SH3 domain of iASPP has an
rmsd of 1.0 A˚ when compared to that of ASPP2 for 61 equivalent
Ca atoms.
The ankyrin repeats and SH3 domain form interdomain hydro-
gen bonds between Gln 753 in the second a helix of the fourth
ankyrin repeat and Arg 790 positioned in the n-Src loop of
the SH3 domain and between Asn 685 in the b-hairpin loop of
the second ankyrin repeat and Arg 820 in the C terminus of the
SH3 domain. The interface is further stabilized by a network of
hydrophobic interactions.
Characteristics of the p53 Binding Site in iASPP
The putative p53 binding site in iASPP broadly resembles that of
ASPP2. The major interactions between the C-terminal region of
ASPP2 and the p53 DNA binding domain, as previously reported
(Gorina and Pavletich, 1996) (PDB code: 1YCS), aremade via the
SH3 domain, which interacts with the L3 loop of p53. Further
interactions are made by the b-hairpin loop of the third ankyrin
repeat, which interacts with the L2 loop of p53 (Gorina and Pav-
letich, 1996). The ASPP2 residues involved in binding the DNA
binding domain of p53 aremapped onto the sequence alignment
presented in Figure 2B. Many of the residues involved are con-
served in iASPP but there are differences. Of the eight residues
of ASPP2 that form hydrogen bonds with p53, five of these res-
idues are identical in iASPP (Ser 725, Tyr 769, Asp 775, Glu 776,
and Trp 798), but residues Thr 722, Phe 773, and Glu 794 differ
from those at the equivalent positions in ASPP2 (Figures 3B
and 3C). Of the ten ASPP2 residues observed to make hydro-
phobic contacts with p53, five are conserved in iASPP (Ser
725, Glu 795, Trp 798, Tyr 809, and Asn 813). Of those that are
not identical, the majority are replaced by residues with similar
chemical properties except for iASPP residues Leu724, Gly
727, and Phe 773, which respectively replace Tyr, Met, and
Asn in ASPP2 (Figures 3B and 3C).
Although our solid phase binding assay showed similar affini-
ties for p53core binding to iASPPD625 and ASPP2D905 their
structures contain significant differences, which could be ex-
ploited for drug design. In contrast, p63core and p73core binding
affinities discriminate between iASPPD625 and ASPP2D905;
these results are quantified and depicted in Figure 1. In sum-
mary, iASPP binds p63 and p73 with approximately 3-fold higher
affinity than ASPP2. Numerous residue differences may contrib-
ute to this effect (Figures 3B and 3C and Figure S1, see the Sup-
plemental Data available with this article online). Previous publi-
cations have highlighted the potential importance of ASPP2 Leu
Figure 3. Comparison of iASPP and ASPP2
(A) Superposition of the iASPP and ASPP2 (PDB code: 1YCS) structures. Only
the ankyrin repeats have been considered in the structural alignment calcula-
tion. The iASPP structure is colored blue, and ASPP2 is in red. The difference in
relative orientations between ankyrin repeats and SH3 domains for the
compared structures is indicated. For orientation purposes, the side chains
of N-terminal iASPP residues Arg 618 and Arg 624 are depicted as sticks (in
atomic coloring: carbon: yellow; nitrogen: blue).
(B andC) Comparisons of the p53 binding site betweenASPP2 and iASPP. p53
is colored green, ASPP2 orange, and iASPP cyan; relevant residues are de-
picted as sticks (in atomic coloring: carbon: yellow; nitrogen: blue; oxygen:
red), residue identities without brackets represent ASPP2, and those in
brackets, iASPP. (B) Close up views of the L3 loop of p53 and the RT-loop in-
teraction surface (C) and the L2 loop of p53 and the b hairpin loop interface.
(D) Interactions between iASPP molecules in the crystal packing. The upper
molecule is orientated and colored as in (A) and for orientation purposes the
side chains of N-terminal iASPP residues Arg 618 and Arg 624 are depicted
as sticks as in (A); the neighboring iASPP molecule is colored as in Figure 2;
the position of Arg 624 is shown but not that of Arg 618due to space constraints.
(E) Ribbon presentation of ASPP2-p53 crystal structure (PDB code: 1YCS).
ASPP2 is colored and orientated as in (A). p53 is in green. The interacting L2
and L3 loops are labeled. It can be seen that lattice contacts in the iASPP crys-
tal occur at the putative p53 binding site. Sequence differences between the
core domains of p53 family members can be observed in the sequence align-
ment presented in Figure S1.
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maschi et al., 2006; Gorina and Pavletich, 1996); however, this
remains speculative.
A Novel Interaction Potential Revealed by iASPP Crystal
Packing
One unexpected property of the iASPPD608 crystal structure is
revealed by the crystal packing. The first eight ordered N-
terminal residues of one iASPPD608 molecule, residues 616–
623 (SPRKARRA), occupy the putative p53 binding site of the
neighboring molecule in the crystal lattice (Figures 3D and 3E).
Figure 4. Interactions of the N Terminus of
One iASPPD608 Molecule with the Putative
p53 Binding Site of the Neighboring Mole-
cule in the Crystal Lattice
(A) Composite omit map at 1 s of the iASPPD608
N-terminal residues (depicted as sticks in atomic
coloring: carbon: yellow; nitrogen: blue; oxygen:
red) bound to a neighboring molecule, which is
drawn as solvent accessible surface colored by
electrostatic potential.
(B) Interactions of the iASPPD608 N-terminal resi-
dues depicted in sticks and colored as in (A) with
the neighboring molecule. Residues interacting
with the iASPPD608 N-terminal residues are high-
lighted as sticks in atomic coloring (SH3 domain
carbon: cyan; ankyrin repeats carbon: magenta;
nitrogen: blue; oxygen: red). Red dotted lines rep-
resent hydrogen bonds. The orientation is as in (A).
(C) Schematic representation of the interactions
between the N terminus of one iASPPD608 with
the neighboring molecule in the crystal lattice cal-
culated with program LIGPLOT (Wallace et al.,
1995). The N terminus of iASPPD608 and the cor-
responding interacting residues of the neighboring
molecule are drawn in stick presentation (N-termi-
nal iASPP carbon: orange; neighboring iASPP
carbon: black; oxygen: red; nitrogen: blue) Water
molecules are shown as yellow spheres. Cyan dot-
ted lines represent hydrogen bonds with the
lengths in A˚, and red eyelashes represent hydro-
phobic interactions.
The majority of the interactions are
made with the SH3 domain, but there
are also contributions from the third an-
kyrin repeat (Figures 4A–4C). iASPP resi-
dues 616–623 are orientated with the N
terminus interacting with the ankyrin re-
peats and the subsequent residues lying
in the SH3 peptide binding groove. Pro
617 interacts with the RT-loop and the
helical segment of the SH3 domain, Arg
618 is sandwiched between the b-hairpin
loop of the third ankyrin repeat and the
310 helical segment of the SH3 domain
forming hydrogen bonds to the main
chain of Thr 722. Lys 619 interacts with
the 310 helical segment and is hydrogen
bonded to Glu 772 of the RT loop of the
SH3 domain; Ala 620 is in van-der-Waals
contact with the n-Src loop. Arg 622 is coordinated by hydrogen
bonds to Asp 775 andGlu 776 of the RT loop andGlu 795 located
on the n-Src loop, and finally Ala 623 interacts with the n-Src
loop. Figures 4A–4C details all the interactions made between
the two iASPP molecules.
Residues 616–623 bury 1100 A˚2 of solvent accessible surface
on iASPP, similar to that observed in SH3 domain-peptide co-
structures (Harkiolaki et al., 2003; Wu et al., 1995). The residues
bind the SH3 domain in the minus orientation (for a definition
see Feng et al. [1994] and Lim et al. [1994]), interacting with a
surface that shows a high level of conservation (Figure 5A)
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1994; Wu et al., 1995). Many of the SH3 residues involved in the
interaction (Glu 776, Trp 798, Pro 811, Asn 813, and Tyr 814)
are highly conserved and mediate ligand binding in classical
SH3 domain costructures (Figure 5B). A BLAST search (http://
www.ncbi.nlm.nih.gov/) showed that residues 616–623 are
unique to iASPP, and these residues are conserved between
the human and mouse proteins.
To further characterize the binding properties of the
iASPPD608 N terminus by isothermal titration calorimetry (ITC),
the construct iASPPD625 lacking the interacting N-terminal res-
idues was used, and a peptide synthesized comprising iASPP
residues 616–623 (peptide P1). ITC experiments were performed
as described in the Experimental Procedures section. Represen-
tative data for titration of iASPP with the P1 peptide are shown in
Figure S2. Following an appropriate correction for heat of
peptide dilution, analysis of the data provided reproducible Kd
values. Our results suggest that each iASPP molecule binds
one peptidemolecule with an estimated Kd of 45 mM, the average
of three separate experiments.
DISCUSSION
The iASPPD608 crystal structure shows that the C-terminal do-
main of iASPP is made up of four ankyrin repeats and a closely
juxtaposed SH3 domain that form a single structural unit with
a significant buried surface area between the two protein motifs.
The close proximity of the ankyrin repeats and the SH3 domain is
a characteristic feature of ASPP proteins; indeed, so far only
ASPP proteins have been shown to adopt a structural unit con-
sisting of ankyrin repeats closely juxtaposed to an SH3 domain.
Without structural information, it is difficult to determine whether
this domain arrangement is present in other proteins as terminal
ankyrin repeats usually deviate from the established consensus
Figure 5. The iASPP Peptide Interacts with the SH3 of iASPP, Binding the Same Conserved Surface as Observed in Many SH3 Domain
Costructures
(A) Solvent-accessible surface representation of the iASPP SH3 domain with the n-SRC loop colored in orange and the RT-loop in red. The iASPP residues
616–623 are shown as cyan ribbon. Superimposed onto the iASPP SH3 domain are the relative positions of peptides observed to interact with the SH3 domains
of ASPP2 (PDB code: 1YCS; seq. identity: 51%; rmsd: 1.0 A˚), C-Crk (PDB code: 1CKA; seq. identity: 36%; rmsd: 0.9 A˚), Mona/Gads (PDB code: 1OEB; seq.
identity: 46%; rmsd: 1.1 A˚), Stam2 (PDB code: 1UJO; seq. identity: 37%; rmsd: 0.9 A˚), and Abi tyrosine kinase (PDB code: 1ABO; seq. identity: 34%; rmsd:
1.3 A˚). The peptides are color-coded as in the far right of (B).
(B) A sequence alignment of the SH3 domains, with the relative peptide sequence positioned to the right of the alignment. The interacting residues of the SH3
domain and the peptide sequences are color coded as follows: blue for residues making hydrogen bonds, red for hydrophobic interactions, and green for res-
idues making both hydrogen bonds and hydrophobic interactions.
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may be present in the proteins CASKIN1 and CASKIN2 (Tabuchi
et al., 2002), which are predicted to have six ankyrin repeats, a 34
residue linker (the approximate average length of an ankyrin
repeat) whose sequence is predicted to contain two helices,
followed by an SH3 domain. The amino acid sequences that
make up the C-terminal ankyrin repeat of iASPP and ASPP2 con-
stitute two a helices and lack a b-hairpin loop.
We have shown that iASPPD625 and ASPP2D905 have a sim-
ilar high affinity for p53core, the Kd value determined for the
ASPP2D905-p53core interaction in our solid-state binding assay
(23 nM) is very similar to results obtained by (Gorina and
Pavletich, 1996) using surface plasmon resonance (30 nM).
iASPPD625 is able to interact with p63core and p73core with
a 3-fold higher affinity than ASPP2D905, raising the possibility
that iASPP, like ASPP2, plays a role in the regulation of p63-
and p73-dependent apoptosis. ASPP1 and ASPP2 have been
shown to bind all p53 family members and stimulate the transac-
tivation function of p53, p63, and p73 on the promoters of
apoptotic genes (Bergamaschi et al., 2004; Samuels-Lev et al.,
Table 1. Crystallographic Statistics
Data Collection
Beamline ESRF-ID14EH2
Resolution 30.0–2.1 (2.2–2.1)
Spacegroup P21212
Cell dimensions (A˚) a = 60.0
b = 67.5
c = 50.5
Wavelength (A˚) 0.9757
Unique reflection 12454 (1610)
Completeness (%) 99.1 (96.0)
Rmerge (%)
a 11.7 (71.6)
I/sI 10.3 (1.9)
Average redundancy 4.3 (2.7)
Reflections with I/sIR 2 (%) 82.9 (60.3)
Refinement
Resolution range (A˚) 30.0–2.1 (2.2–2.1)
Number of reflections 11554 (1600)
Rfactor (%)
b 20.8 (33.0)
Rfree (%)
c 25.8 (37.4)
Rmsd bonds (A˚) 0.006
Rmsd angles () 1.20
Rmsd main-chain bond B (A˚2) 1.44
Rmsd side-chain bond B (A˚2) 2.39
No. of atoms per asymmetric unit
(protein/water)
1592/154
Average B factors (protein/water) (A˚2) 32.1/39.7
Numbers in parentheses refer to the appropriate outer shell. Rmsd: root
mean square deviation from ideal geometry.
a Rmerge = Shkl SijI(hkl;i) < I(hkl) > j/Shkl SiI(hkl;i), where I(hkl;i) is the inten-
sity of an individual measurement, and < I(hkl) > is the average intensity
from multiple observations.
bRfactor = ShkljjFobsj  kjFcalcjj/Shkl jFobsj.
c Rfree equals the R factor against 5% of the data removed prior to refine-
ment.Structure 16,2001). Our data now provide comparable biochemical affinity
measurements for iASPP and ASPP2 binding p53, p63, and
p73. Relative to functional data, analysis of our crystal structure
suggests some reasons why compared to ASPP2D905,
iASPPD625 has an approximate 3-fold greater affinity for
p63core and p73core. The iASPPD608 crystal packing suggests
that a peptide based on the sequence of iASPP residues 616–
623would have the appropriate properties to bind to the C-termi-
nal part of iASPP. This peptide binding site overlaps the putative
binding site on iASPP for the DNA-binding domain of p53, and
thus such peptides (or polypeptide sequences) would be pre-
dicted to compete with p53 for iASPP binding. ITC experiments
confirmed that a synthetic peptide corresponding to residues
616–623 can indeed bind the C-terminal domain of iASPP with
a binding affinity comparable to previously measured SH3-pep-
tide interactions (Dalgarno et al., 1997).
The inhibition of iASPP binding to p53 could be a potential
cancer therapy (Bergamaschi et al., 2003; Trigiante and Lu,
2006). SH3 domains have proved to be difficult targets for drug
design as most SH3 ligands show crossreactivity with several
SH3 domains (Feng et al., 1994, 1995; Knudsen et al., 1995;
Lim et al., 1994; Wu et al., 1995). However, the uniqueness of
the p53 binding site, made up of contributions from both the
SH3 domain and the third ankyrin repeat, may provide a drug-
gable target; a space-filling picture of this target site is shown
in Figure S3. The protein-protein interactions observed in the
iASPP crystal provide a starting point for structure-based drug
design. For example, residues Arg 618 and Lys 619, from a
neighboring molecule in the crystal lattice, interact with residues
unique to iASPP (not present in ASPP1 or ASPP2) such as Thr
722 and Leu 724. A small molecule that mimicked this interaction
could specifically block the p53 binding site of iASPP and pro-
vide a novel strategy for inhibition of this oncoprotein.
EXPERIMENTAL PROCEDURES
Plasmid Construction, Protein Expression, and Purification
For solid-phase binding experiments, two ASPP constructs, iASPPD625 and
ASPP2D905 encoding iASPP residues 625–628 and ASPP2 residues
905–1128, respectively, were made by using the bacterial expression vector
pET22b (Novagen). Nucleotides encoding the required amino acids were am-
plified by PCR introducing a hexa-histidine sequence in 50 and a stop codon in
30, cloned into the expression vector by using NdeI and EcoRI restriction sites,
and sequenced. Constructs encoding the DNA-binding domain of p53 resi-
dues 94–292 (p53core), p63 residues 123–323 (p63core), and p73 residues
112–312 (p73core), used in solid phase binding assays, were also made by us-
ing pET22b essentially as for ASPP constructs but without the incorporation of
a hexa-histidine coding sequence.
For crystallization experiments, the construct iASPPD608 encoding human
iASPP residues 608–828 wasmade by using the same strategy as for the other
ASPP constructs. ASPP proteins were expressed in the E. coli strain Rosetta
pLysS (Invitrogen), bacteria were grown in Luria broth (LB) with 100 mg/ml am-
picillin, and protein expression induced by addition of 0.25 mM ispropyl-b-D-
thiogalactopyranoside (IPTG). Bacterial pellets were suspended in ice-cold
high salt PBS (500 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4/NaH2PO4 [pH
8.0]), lysed by sonication, and clarified by centrifugation. Recombinant pro-
teins were purified from the soluble fraction by Ni2+ affinity chromatography
and then further purified by size exclusion chromatography into the appropri-
ate buffer. The recombinant proteins p53core, p63core, and p73core were puri-
fied as previously described for the DNA-binding domain of p53 (Derbyshire
et al., 2002).259–268, February 2008 ª2008 Elsevier Ltd All rights reserved 265
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Purified iASPPD625, ASPP2D905, p53core, p63core, and p73core were buffer
exchanged by size exclusion chromatography into PBS (137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4/NaH2PO4 [pH 7.4]). The DNA-binding domains
of p53, p63, and p73 were immobilized on 96-well microtiter plates (Nunc, Pol-
ySorp), 10 pM per well, over night at 4C. Remaining binding sites were satu-
rated by 1 hr incubation at 4C in PBS containing 1% bovine serum albumin
(BSA). Microtiter plates were incubated for 1 hr at 4C with a dilution series
of either iASPPD625 or ASPP2D905 and then incubated with 1/1000 dilution
of monoclonal antibody solution (anti-iASPP LX142.1 [raised against
iASPPD625] or anti-ASPP2 LX141.2 [raised against ASPP2D905]), plates
were then probed for 1 hr at 4C with an anti-mouse IgG alkaline phosphatase
conjugate antibody (Sigma-Aldrich). The bound alkaline phosphatase conju-
gate antibody was detected by the addition of the substrate p-Nitrophenyl
Phosphate. Progress curves were recorded for 40 min at room temperature,
at 405 nm, with a Thermo Labsystems Multiskan Ascent microplate reader,
and the initial rates were determined with the SigmaPlot 10 software (Systat
Software, Inc.). Each data point represents the average of duplicate wells, ±
the standard deviation; error bars represent the standard deviation of dupli-
cate measurements. Nonspecific binding was determined from iASPPD625
or ASPP2D905 bound to BSA and was subtracted from each data point.
Data points were plotted, rate term against ligand concentration, resulting in
saturation curves. Scatchard analysis was also undertaken. In order to deter-
mine Kd values, saturation curves were fitted by nonlinear regression analysis
with the SigmaPlot 10 software.
iASPP Crystallization and Data Collection
Prior to crystallization, iASPPD608 was concentrated by ultrafiltration in size
exclusion buffer (150 mM NaCl, 25 mM Tris [pH 8.0], 1 mM DTT) to 8 mg/ml.
Sitting drop vapor diffusion crystallization trials (drop size: 100 nl protein
plus 100 nl reservoir solution) were set up with a Cartesian robot as previously
reported (Brown et al., 2003; Walter et al., 2003). iASPPD608 initially crystal-
lized at 20C out of a mother liquor containing 20% (w/v) PEG 3350, 0.2 M
potassium chloride (Hampton Peg/Ion screen, reagent 8). Optimized crystals
grow at 20C out of a mother liquor containing 22% (w/v) PEG 3350, 0.3 M po-
tassium chloride, and 17.5% MPD. The crystals cryo-protected in mother
liquor diffracted to 2.1 A˚ after flash freezing at 100 K on beamline ID14EH2
at the ESRF. X-ray data were processed and scaled with the HKL suite (Otwi-
nowski and Minor, 1997). The program XPREP (http://www.bruker-nonius.
com/) was used to calculate quality indicators and to merge data. Crystallo-
graphic statistics are shown in Table 1.
Structure Determination and Refinement
The iASPPD608 crystal structure was determined by using the molecular re-
placement method. Real space crossrotation function, PC refinement of the
rotation peaks, and fast F2F2 translation searches within a data range of 15–
3 A˚ with the program CNS (Bru¨nger et al., 1998) by using the structure coordi-
nates of ASPP2 (PDB code: 1YCS, sequence identity: 53%) as the search
model resulted in the correct orientation and position of the iASPP monomer
in the crystallographic asymmetric unit. Refinement was carried out with pro-
grams REFMAC (Murshudov et al., 1997) and CNS by iterative cycles of sim-
ulated annealing, conjugate gradient minimization, individual B factor refine-
ment, and manual rebuilding with program O (Jones et al., 1991). Final
refinement resulted in an R factor (Rfree) of 20.8% (25.8%) (see also crystallo-
graphic statistics in Table 1). The stereochemical properties of the structure
were assessed by PROCHECK (Laskowski et al., 1993) and WHATCHECK
(Hooft et al., 1996) and showed no residue in disallowed regions of the Ram-
achandran plot. Structural superpositions were made with the program SHP
(Stuart et al., 1979), and all figures were produced with Pymol (http://pymol.
sourceforge.net/).
Isothermal Titration Calorimetry
For ITC measurements, a peptide corresponding to iASPP amino acids 616–
623 (SPRKARRA), termed P1, was synthesized by using standard technology
and purified by high-pressure liquid chromatography (ALTA Bioscience, Bir-
mingham). Experiments were performed with a VP-ITC microcalorimeter (Mi-
croCal, Northampton,MA). Purified iASPPD625was dialyzed into a buffer con-
sisting of 50 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4/NaH2PO4 (pH 8.0). The266 Structure 16, 259–268, February 2008 ª2008 Elsevier Ltd All rigdialysis buffer was also used to dissolve the peptide. At a concentration of 1.5
mM, P1 was titrated from a syringe (300 ml total volume) into a sample cell con-
taining 1.4 ml iASPPD625 (0.1 mM). Prior to experiments, both peptide and
protein solutions were clarified for 10 min at 16,100 3 g and degassed (Ther-
moVac; MicroCal). At the equilibrium temperature of 15C, peptide P1 was ti-
trated into iASPPD625 by 44 injections of 5 ml each. Resulting peaks of mea-
sured deviations from the equilibrium temperature were integrated to yield
the quantity of heat generated. The control experiment, injecting the peptide
at the above concentration into buffer alone, by the same experimental condi-
tions, to find the heat generated by peptide dilution, was performed, and the
integrated data were subtracted from peptide into protein data. Heat gener-
ated by protein dilution was determined by injecting buffer alone into a sample
chamber filled with iASPPD625 and was found to be negligible. Data were fit-
ted by c2minimization on amodel assuming a single set of binding sites to cal-
culate the dissociation constant, Kd. All steps of the data analysis were per-
formed with ORIGIN (V7.0) software provided by MicroCal.
Supplemental Data
Supplementary Data include three figures: Figure S1 shows a sequence align-
ment of the DNA binding domains of the human p53 family members, Figure S2
shows a representative isothermal titration calorimetry (ITC) experiment for ti-
trations of iASPPD625 with an iASPP derived peptide, and Figure S3 shows
a space-filling diagram of a cavity in the putative p53 binding site of iASPP.
These data are available with this article online at http://www.structure.org/
cgi/content/full/16/2/259/DC1/.
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